Navigation Links
Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:4/8/2008

SAN DIEGO, April 8, 2008 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) announced today that it initiated screening in a Phase 2b clinical trial of APD125 in patients with primary insomnia. APD125 is an oral drug candidate discovered by Arena with the potential to reduce insomnia symptoms and improve sleep maintenance and quality.

The Phase 2b trial of APD125 is a double-blind, randomized, placebo- controlled subjective study evaluating the efficacy and tolerability of APD125 in patients with primary insomnia characterized by difficulty maintaining sleep. The trial, which is expected to enroll a total of approximately 675 male and female patients in about 70 clinical sites in the United States, will evaluate two doses (20 mg and 40 mg) and placebo over 14 nights of treatment. The trial will evaluate standard subjective measurements of sleep, including change from baseline in subjective number of awakenings after sleep onset (sNAASO), which is the primary endpoint.

"We are very encouraged by the emerging profile of APD125. We believe APD125 has the potential to significantly improve sleep maintenance and quality for patients with insomnia without the potential for dependence or impairing psychomotor function," said Jack Lief, Arena's President and Chief Executive Officer. "Results from this trial are expected around year end, and we believe they will increase our understanding of APD125 while supporting ongoing partnership efforts."

In a Phase 2a trial, when compared to placebo, patients treated with APD125 achieved statistically significant improvements in objective measurements of sleep maintenance, or the ability to maintain sleep during the night after falling asleep, and sleep architecture. T
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
2. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
3. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
4. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... 29, 2014 Research and Markets ... Sclerosis Drugs Market 2014-2018" report to their offering. ... medical condition that results in demyelination, axonal transection, and ... abnormal response by the immune system, which targets neurons ... potentially debilitating disease in which the damage of the ...
(Date:8/29/2014)... 29, 2014 Pixcelldata, the innovative ... has announced a major new deal with Dutch based ... pathology expert, Dr. Marius Nap . ... European Congress of Pathology which is taking placing between ... London where Pixcelldata will demonstrate ...
(Date:8/28/2014)... 28, 2014  Rigrodsky & Long, P.A.: , ... (NYSE: LCI )? , Did you purchase your ... July 16, 2014, inclusive? , Did you lose money ... you want to discuss your rights? ... Attorney, Timothy J. MacFall , announces that a complaint has ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3Pixcelldata Announces New Deal with Dutch Tele-Pathology Specialists eX-Path Ahead of ECP 2014 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
... Systems Ltd. (Nasdaq: DHRM ) ("Dehaier" or ... marketing and sale of medical devices and homecare medical ... Weibing Yang as and Dr. Genhui Chen directors of ... fills the vacancy resulting from the resignation of Ms. ...
...  Researchers have published the largest single patient population ... patients with retrievable inferior vena cava (IVC) filters—devices ... the lungs. This study, which is important for ... existing guidelines developed by the Society of Interventional ...
Cached Medicine Technology:Dehaier Medical Announces Changes to Board of Directors 2Dehaier Medical Announces Changes to Board of Directors 3IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 2IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 3IVC Filters: Society of Interventional Radiology Leads in Patient Care, Safety, Research 4
(Date:8/29/2014)... been hospitalized for a burn as a child experience higher ... new research at the University of Adelaide . , ... conducted by the University,s Centre for Traumatic Stress Studies. ... form of mental illness and 30% suffered depression at some ... the journal Burns , also found that ...
(Date:8/29/2014)... Saturday 30 August 2014: New ESC registries ... coronary syndromes (ACS). The announcement comes as the ... and the study on heart failure patients conducted ... and Development (OECD) begins an outcomes evaluation. , ... EURObservational Research Programme (EORP). , Professor Roberto Ferrari, ...
(Date:8/29/2014)... 2014 Glendale Botox experts at ... Botox throughout the month of September. This special offer features ... syringes of Juvederm. Patients can take advantage of this special ... Glendale Botox experts will work with patients to determine if ... What is Botox? , Botox is a treatment made ...
(Date:8/29/2014)... Aug. 29, 2014 (HealthDay News) -- The way that ... baby,s language development, a new study suggests. Over ... and their infants during free play. The sessions were ... infants were 8 months old at the start of ... a baby,s babbling, infants began to form complex sounds. ...
(Date:8/29/2014)... 29, 2014 Empty Nest Syndrome ... http://www.blogtalkradio.com/dr-carol-francis/2014/08/29/psychologist-dr-carol-francis-addressing-empty-nest-syndrome .     , Mothers and fathers, who ... marital bliss, prodding, laughing and sweating through parenting, ... this week. Relief and parenting pride intermix ... Dr. Carol Francis as a Clinical ...
Breaking Medicine News(10 mins):Health News:Intervention needed for survivors of childhood burns 2Health News:New ESC registries launched on cardiac oncology and ACS 2Health News:New ESC registries launched on cardiac oncology and ACS 3Health News:New ESC registries launched on cardiac oncology and ACS 4Health News:Glenoaks Laser Center is Now Offering a Special Promotion on Botox for the Month of September 2Health News:Encouraging Your Baby's Babbling May Speed Language Development 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 2Health News:Psychologist Dr. Carol Francis Addressing Empty-Nest Syndrome on Talk Radio Today 3
... represents first available generic equivalent of Alkeran(R) , ... Bioniche Pharma, a leading developer and manufacturer of ... the FDA approval and launch of Melphalan Hydrochloride for ... , (Logo: http://www.newscom.com/cgi-bin/prnh/20080702/AQW070LOGO ) , ...
... with poor and intermediate risk of survival, benefit most, researchers ... patients with acute myeloid leukemia (AML) who come out of ... at survival, a new analysis shows. , AML is the ... a year in the United States. Treatment usually involves chemotherapy ...
... colorectal cancer, America,s third leading type of cancer, is ... colorectal cancer deaths could be avoided by simple screening, ... be painful, and current diagnostic techniques are time-consuming and ... the Department of Physical Electronics at Tel Aviv University, ...
... For more than 80 years, Courage Center, the ... leader in incorporating new and innovative technologies into their ... is the first site in the midwest to offer ... person,s walking pattern. , , (Photo: http://www.newscom.com/cgi-bin/prnh/20090609/CG30042 ...
... are getting full when eating a large meal? New research ... partially explain why severely obese individuals may not feel satisfied ... food they consume during a meal. Researchers led by ... Diabetes Research Center focused on habituation, or the idea that ...
... in one trial, but when therapy starts could be key ... diabetes trials show that the relationship between tight blood sugar control ... , The first analysis found that a troubling number of ... to have been caused by low blood glucose levels, as originally ...
Cached Medicine News:Health News:Bioniche Pharma and Synerx Pharma Launch Melphalan Hydrochloride for Injection 2Health News:Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia 2Health News:Donor Stem-Cell Transplant Best For Acute Myeloid Leukemia 3Health News:A real-time diagnosis for a treatable cancer 2Health News:Courage Center Is First in Midwest to Offer Innovative Treatment for Movement Disorders 2Health News:Physiological response may explain why some severely obese patients overeat 2Health News:Effect of Strict Diabetes Control on Heart Still Unclear 2Health News:Effect of Strict Diabetes Control on Heart Still Unclear 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: